Leap Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview

Cypherpunk Technologies

09/05/2023 16:37

* Leap Therapeutics Inc  LPTX.OQ   LPTX.O  is expected
to show no
change in quarterly revenue when it reports  results on May 11
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Leap Therapeutics
Inc is
for a loss of 10 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Leap
Therapeutics
Inc is $2.5​, above​ its last closing price of $0.39. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022              -0.11      -0.10     Beat    9.1
 Sep. 30 2022  -0.12       -0.12      -0.13     Missed  -8.3
 Jun. 30 2022  -0.10       -0.10      -0.15     Missed  -56.2​
 Mar. 31 2022  -0.10       -0.10      -0.09     Beat    10
 ​​Dec.        -0.12       -0.11      -0.10     Beat    9.1
 31 2021                                                
 Sep. 30 2021  -0.10       -0.11      -0.14     Missed  -25​
 Jun. 30 2021  -0.13       -0.12      -0.12     Met     4
 Mar. 31 2021  -0.11       -0.11      -0.12     Missed  -13.2
 This summary was machine generated May 9 at 15:37 GMT.  All
figures in US dollars  unless otherwise stated